100 mg AP1189 ( DrugBank: - )

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
46悪性関節リウマチ1
222一次性ネフローゼ症候群1

46. 悪性関節リウマチ

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05516979
(ClinicalTrials.gov)		September 26, 202224/8/2022A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD TreatmentA Double-blind, Multi-center, Randomized, Placebo-controlled Study of the Safety and Efficacy of 12 Weeks Extended Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients naïve to DMARD TreatmentRheumatoid ArthritisDrug: 100 mg AP1189;Drug: PlaceboSynAct Pharma ApsNBCD A/SRecruiting18 Years85 YearsAll120Phase 2Moldova, Republic of

222. 一次性ネフローゼ症候群

臨床試験数 : 310 /  薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04456816
(ClinicalTrials.gov)		August 31, 202024/6/2020A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe ProteinuriaAn Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe ProteinuriaNephrotic Syndrome Due to Idiopathic Membranous Nephropathy;Severe Proteinuria Due to Idiopathic Membranous NephropathyDrug: 100 mg AP1189;Drug: PlaceboSynAct Pharma ApsNULLRecruiting18 Years85 YearsAll23Phase 2Denmark